证券代码：603658 证券简称：安图生物 公告编号：2025-038 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理 赎回及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 现金管理种类：大额存单 现金管理金额：33,000 万元非公开发行股票闲置募集资金； 履行的审议程序：郑州安图生物工程股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次会 议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》，同意 公司在确保不影响募集资金投资项目建设和募集资金使用的情况下，公司 拟分别使用不超过 1.7 亿元公开发行可转换公司债券闲置募集资金和不超 过 17 亿元非公开发行股票闲置募集资金进行现金管理，分别用于购买单次 持有期限不超过 12 个月的结构性存款、大额存单、国债逆回购、券商收益 凭证、券商理财产品等安全性高、流动性好的保本型产品。在上述额度范 围内，资金可在 12 个月内滚动使用。具体内容详见公司于 2024 ...

证券代码：603658 证券简称：安图生物 公告编号：2025-037 （二）现金管理金额 公司非公开发行股票闲置募集资金 25,000 万元 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理 赎回及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 现金管理种类：大额存单 现金管理金额：25,000 万元非公开发行股票闲置募集资金； 履行的审议程序：郑州安图生物工程股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次会 议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》，同意 公司在确保不影响募集资金投资项目建设和募集资金使用的情况下，公司 拟分别使用不超过 1.7 亿元公开发行可转换公司债券闲置募集资金和不超 过 17 亿元非公开发行股票闲置募集资金进行现金管理，分别用于购买单次 持有期限不超过 12 个月的结构性存款、大额存单、国债逆回购、券商收益 凭证、券商理财产品等安全性高、流动性好的保本型产品。在上述额度 ...

Core Viewpoint - The company has established a dedicated settlement account for cash management of temporarily idle raised funds, ensuring compliance with regulations and enhancing the efficiency of fund utilization [2][3][4]. Group 1: Cash Management Plan - The company plans to use up to 170 million yuan from publicly issued convertible bonds and up to 1.7 billion yuan from non-publicly issued stock for cash management, focusing on safe and liquid financial products [2]. - The cash management will involve purchasing structured deposits, large certificates of deposit, treasury reverse repos, and other high-security, principal-protected products, with a holding period not exceeding 12 months [2][3]. Group 2: Account Establishment - A specialized settlement account for cash management has been opened at Zhengzhou Bank, specifically for the temporarily idle funds from the company's 2020 non-public stock issuance [3]. - The account will only be used for cash management of the raised funds and will not hold non-raised funds or serve other purposes [3]. Group 3: Risk Control Measures - The company will adhere to relevant regulations and guidelines in managing cash, including the Shanghai Stock Exchange rules and company bylaws [4]. - There will be a monitoring system in place to assess potential risks associated with investment products, with independent oversight from the board and audit committee [4]. Group 4: Impact on the Company - The cash management of idle funds will not affect the normal operation of fundraising projects or the company's main business, ensuring that shareholder interests are protected [4]. - This strategy is expected to improve the efficiency of fund utilization and increase returns on cash assets for the company and its shareholders [4].

Investment Rating - The investment rating for the company is "Buy" indicating an expected relative price increase of over 20% compared to the market benchmark index within the next six months [22]. Core Views - The company's performance is under short-term pressure, with expectations for recovery driven by overseas expansion and domestic market recovery [2][4]. - The company reported a revenue of 4.471 billion (up 0.62% year-on-year) and a net profit of 1.194 billion (down 1.89% year-on-year) for 2024, while Q1 2025 saw a revenue of 996 million (down 8.56% year-on-year) and a net profit of 270 million (down 16.76% year-on-year) [3][5]. - The company is actively responding to centralized procurement impacts, with expectations for recovery in the second quarter of 2026 [5]. Financial Performance - In 2024, the company achieved revenue of 25.56 billion in immunodiagnostics (up 2.91% year-on-year), while biochemical testing revenue was 2.22 billion (down 11.21% year-on-year), and microbiological testing revenue was 3.61 billion (up 11.48% year-on-year) [5]. - The overseas business generated revenue of 284 million in 2024 (up 36.25% year-on-year), indicating strong growth potential [6]. - The company maintained stable expense ratios, with a sales expense ratio of 17.2%, management expense ratio of 4.7%, and R&D expense ratio of 16.4% (up 1.6 percentage points) [6]. Product Development and Market Position - The company launched new products including the AutoChem B2000 and B8000 series of fully automated biochemical analyzers, and the Autof T series of microbial mass spectrometry detection systems [6]. - In the NGS segment, the company’s subsidiary successfully launched three gene sequencers and an automated pathogen analysis system, with further products in trial production [6]. Earnings Forecast and Valuation - The earnings per share (EPS) forecast for 2025-2027 is 2.2, 2.6, and 3.0 respectively, with corresponding price-to-earnings (PE) ratios of 17, 15, and 13 [7]. - The company is recognized as a pioneer in the domestic IVD platform, with increased R&D investment expected to enhance competitiveness [7].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"）于2024年12月11日召 开第五届董事会第二次会议、第五届监事会第二次会议，审议通过《关于使用闲 置募集资金进行现金管理的议案》，同意公司在确保不影响募集资金投资项目建 设和募集资金使用的情况下，公司拟分别使用不超过1.7亿元公开发行可转换公 司债券闲置募集资金和不超过17亿元非公开发行股票闲置募集资金进行现金管 理，分别用于购买单次持有期限不超过12个月的结构性存款、大额存单、国债逆 回购、券商收益凭证、券商理财产品等安全性高、流动性好的保本型产品。在上 述额度范围内，资金可在12个月内滚动使用。具体内容详见公司于2024年12月12 日在上海证券交易所网站（www.sse.com.cn）披露的《安图生物关于使用闲置募 集资金进行现金管理的公告》（公告编号：2024-093）。 证券代码：603658 证券简称：安图生物 公告编号：2025-036 郑州安图生物工程股份有限公司 关于开立募集资金现金管理产品专用结算账户的 公告 ...

Investment Rating - The investment rating for the company is "Buy" [6][12] Core Views - The company is a leading player in the in vitro diagnostics sector, with a diversified business layout that continues to grow [6][12] - In 2024, the company is expected to achieve revenue of 4.471 billion yuan, representing a growth of 0.62%, while the net profit attributable to the parent company is projected to be 1.194 billion yuan, a decrease of 1.89% [6][12] - The company's main business operations are stable, with notable performance in molecular diagnostics and overseas markets [2][6] Financial Performance Summary - For 2024, the company's revenue is projected to be 44.71 billion yuan, with a slight increase of 0.62%, and the net profit is expected to be 11.94 billion yuan, down by 1.89% [2][4] - In Q1 2025, the company reported revenue of 9.96 billion yuan, a decrease of 8.56%, and a net profit of 2.70 billion yuan, down by 16.76% [2][4] - The revenue from the reagent segment in 2024 is expected to be 37.97 billion yuan, with immunodiagnostic products contributing 25.56 billion yuan, an increase of 2.91% [2][4] - The company achieved domestic revenue of 41.05 billion yuan in 2024, a decrease of 1.30%, while overseas revenue reached 2.84 billion yuan, an increase of 36.25% [2][4] Research and Development Summary - The company increased its R&D investment to 7.32 billion yuan in 2024, a year-on-year increase of 11.55% [2][4] - In 2024, the company registered 144 new reagent product certificates, covering advanced technology fields such as chemiluminescence and molecular diagnostics [2][4] - The launch of the AutoChem B2000/B800 series of fully automated biochemical analyzers marks a significant development in the biochemical product field [2][4] Profitability and Financial Ratios - The company's gross margin for 2024 is projected to be 65.41%, reflecting a stable performance [2][4] - The sales, management, and R&D expense ratios for 2024 are expected to be 17.17%, 4.72%, and 16.37%, respectively [2][4] - The projected EPS for 2025, 2026, and 2027 are 2.24 yuan, 2.66 yuan, and 3.08 yuan, respectively [2][4]

Core Points - The company announced a cash dividend of 1.26 yuan per share for its A shares [1] - The total cash dividend distribution amounts to approximately 720 million yuan based on the total share capital of 571,424,768 shares [1] - The dividend distribution plan was approved at the annual shareholders' meeting held on May 8, 2025 [1] Dividend Distribution Details - The record date for the dividend is May 23, 2025, with the last trading date and ex-dividend date both set for May 26, 2025 [1] - The cash dividends will be distributed through China Securities Depository and Clearing Corporation Limited Shanghai Branch [1][2] - For individual shareholders and securities investment funds, the actual cash dividend after tax will be 1.26 yuan per share, with specific tax implications based on holding periods [3][4] Tax Implications - Individual shareholders holding shares for less than or equal to one month will incur a tax rate of 20% on the dividend [3] - Shareholders holding shares for more than one month but less than or equal to one year will have a reduced tax rate of 10% [3] - Shareholders holding shares for over one year will be exempt from personal income tax on the dividend [3] QFII and Other Investors - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax applied, resulting in an actual cash dividend of 1.134 yuan per share [4][5] - Hong Kong market investors will also face a 10% withholding tax, leading to the same net dividend of 1.134 yuan per share [5] - Other institutional investors are responsible for their own tax payments, receiving the gross dividend of 1.26 yuan per share [5]

证券代码：603658 证券简称：安图生物 公告编号：2025-035 郑州安图生物工程股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利1.26元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/5/23 | － | 2025/5/26 | 2025/5/26 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 8 日的2024年年度股东大会审议通过。 本次利润分配以方案实施前的公司总股本571,424,768股为基数，每股派发现金红利1.26 元（含税），共计派发现金红利719,995,207.68元。 1. 发放年度：2024年年度 2. 分派对象： 三、 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红 ...

Investment Rating - The report maintains an investment rating of "Outperform the Market" for the medical device industry [2]. Core Insights - The report emphasizes that AI in healthcare is restructuring diagnostic and treatment processes, creating investment opportunities driven by efficiency and market growth. The global healthcare sector faces challenges such as aging populations and uneven distribution of medical resources, which AI can address by optimizing the healthcare value chain and promoting equitable access to medical resources [5][6]. Summary by Sections 1. AI Healthcare Development Environment - The domestic AI healthcare development environment is mature, supported by data resources and services that enhance algorithm accuracy and generalization [11]. - AI technology is breaking the uneven distribution of medical resources, addressing the growing demand for healthcare services due to an aging population [18][19]. 2. AI Medical Imaging - AI medical imaging is the most mature application of AI in healthcare, with a complete ecosystem covering various imaging modalities such as CT, MRI, and X-ray. The market for AI medical imaging in China is projected to reach 6.17 billion yuan by 2025 [5][39]. - Companies like Mindray and United Imaging are leveraging hardware advantages to build "device + AI" ecosystems, while pure AI companies focus on lesion recognition and cross-disease generalization capabilities [5][39]. 3. AI In Vitro Diagnostics - The AI in vitro diagnostics market is rapidly growing, with applications in hematology, microbiology, and pathology. Companies like BGI and Anbiping are innovating with AI-driven solutions to enhance diagnostic efficiency [5][6]. 4. AI Wearable Devices - AI wearable devices are transforming health management by providing real-time monitoring and data analysis, becoming essential for chronic disease management. The market for smart wearable devices in China is expected to exceed 15 billion yuan in 2023 and reach 33 billion yuan by 2026, with a compound annual growth rate of 18.1% [6]. 5. Investment Recommendations - The report suggests that the industry is poised for multidimensional development, transitioning from scale expansion to higher-level growth. It highlights long-term investment opportunities in leading companies like Mindray, United Imaging, Yuyue Medical, and Kefu Medical, which are early adopters of AI healthcare solutions [6].

特此公告。 证券代码：603658 证券简称：安图生物 公告编号：2025-034 郑州安图生物工程股份有限公司董事会 2025 年 5 月 14 日 郑州安图生物工程股份有限公司 关于参加河南辖区上市公司 2025 年投资者网上集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，郑州安图生物工程股份有限公司（以下 简称"公司"）定于 2025年5月22日（周四）15:25-16:55 参加在全景网举办的 河南辖区上市公司2025年投资者网上集体接待日活动，本次活动将采用网络远程 的方式举行，投资者可登录 "全景 • 路演天下"（http://rs.p5w.net）参与本次 互动交流。 出席本次网上集体接待日活动的人员为公司副总经理兼董事会秘书房瑞宽 先生（如有特殊情况，参会人员将可能进行调整），届时将通过网络在线问答互 动的形式，与投资者就其关注的问题进行交流。欢迎广大投资者积极参与。 ...